Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.
CITATION STYLE
Yang, T. T., Chen, W. H., Zhao, Y. M., Fu, H. R., Huang, H., & Shi, J. M. (2021). Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.672052
Mendeley helps you to discover research relevant for your work.